Page last updated: 2024-12-08

5-diazo-4-oxonorvaline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5-diazo-4-oxonorvaline: RN given refers to (L)-isomer; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID152231
SCHEMBL ID4078056
MeSH IDM0042697

Synonyms (12)

Synonym
17808-06-9
2-amino-5-diazolevulinic acid
l-norvaline, 5-diazo-4-oxo-
5-diazo-4-oxonorvaline
nsc 117613
5-diazo-4-oxo-l-norvaline
l-donv
SCHEMBL4078056
(2s)-2-amino-5-diazo-4-oxopentanoic acid
(4-amino-4-carboxy-2-oxobutylidene)-iminoazanium
DTXSID501312718
PD195590

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Subsequent elimination from plasma was monoexponential with a half-life of 6 +/- 1 days."( Pharmacokinetics of PEG-L-asparaginase and plasma and cerebrospinal fluid L-asparagine concentrations in the rhesus monkey.
Balis, FM; Berg, SL; Godwin, KS; McCully, CL; Poplack, DG, 1993
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (22.22)18.7374
1990's5 (55.56)18.2507
2000's1 (11.11)29.6817
2010's1 (11.11)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.26

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.26 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.26)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (11.11%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (88.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]